Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NKTR-105
- Development stage
- Discontinued
- Lead developer
- Nektar Therapeutics
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
NKTR-105 is a novel PEGylated polymer-drug conjugate of the taxane chemotherapy agent docetaxel, developed by Nektar Therapeutics using its proprietary polymer conjugate technology. By attaching polyethylene glycol (PEG) chains to docetaxel, NKTR-105 is designed to optimize the pharmacokinetic profile of the parent drug, resulting in a prolonged half-life and enhanced accumulation within tumor tissues via the enhanced permeability and retention (EPR) effect. Like docetaxel, its mechanism of action involves binding to and stabilizing microtubules, thereby inhibiting cell division and inducing apoptosis. NKTR-105 was evaluated in Phase 1 clinical trials for the treatment of various advanced solid tumors, including breast, lung, and prostate cancers, with the goal of improving efficacy and reducing systemic toxicities such as neutropenia compared to standard docetaxel.
- Other names
- PEG-docetaxelPEGylated docetaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on NKTR-105.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NKTR-105.